Koninklijke Philips NVRYLPF +2.21%70 Debt-to-EBITDA is 3.76 as of Mar. 2026, which is 40% above its 10-year median of 2.69. GuruFocus rates RYLPF with a GF Score™ of 70/100 and a GF Value™ of $26.00 (Fairly Valued). The stock has 3 warning signs investors should review. Among 468 Medical Devices & Instruments companies, Koninklijke Philips NV ranks worse than 70.3% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Koninklijke Philips NV's Debt-to-EBITDA or its related term are showing as below:
RYLPF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.41 Med: 2.69 Max: 63.84
Current: 3.03
During the past 13 years, the highest Debt-to-EBITDA Ratio of Koninklijke Philips NV was 63.84. The lowest was 1.41. And the median was 2.69.
RYLPF's Debt-to-EBITDA is ranked worse than 70.3% of 468
companies
in the Medical Devices & Instruments industry
Industry Median: 1.555
vs RYLPF: 3.03
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Koninklijke Philips NV Debt-to-EBITDA Related Terms
Koninklijke Philips NV Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Koninklijke Philips NV's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Koninklijke Philips NV's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Koninklijke Philips NV Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Koninklijke Philips NV's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Koninklijke Philips NV's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Koninklijke Philips NV (RYLPF) has a Debt-to-EBITDA of 3.76 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Koninklijke Philips NV. This is 40% above median its historical median of 2.69. Over the past decade, Koninklijke Philips NV's Debt-to-EBITDA has ranged from 1.41 to 63.84. According to the industry distribution chart, Koninklijke Philips NV ranks #329 out of 468 companies in the Medical Devices & Instruments industry, placing it in the top 70.3%.
Is Koninklijke Philips NV's Debt-to-EBITDA too high?
Koninklijke Philips NV's current Debt-to-EBITDA of 3.76 is 40% above median its 10-year median of 2.69. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 63.84. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.56. Koninklijke Philips NV's value of 3.76 is 141.8% above this industry median. Based on the distribution chart, Koninklijke Philips NV ranks #329 out of 468 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Koninklijke Philips NV has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Koninklijke Philips NV's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Koninklijke Philips NV ranks #329 out of 468 companies for Debt-to-EBITDA. This places Koninklijke Philips NV in the lower half of its industry. The industry median Debt-to-EBITDA is 1.56. Koninklijke Philips NV's value of 3.76 is 141.8% above this benchmark. Historically, Koninklijke Philips NV's own Debt-to-EBITDA has ranged from 1.41 to 63.84 over the past decade. While the company's 10-year median is 2.69 vs. the industry median of 1.56, Koninklijke Philips NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.56, based on 468 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Koninklijke Philips NV's current Debt-to-EBITDA of 3.76 is 141.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Koninklijke Philips NV. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Koninklijke Philips NV's current Debt-to-EBITDA is 3.76, which is 40% above median its own 10-year median of 2.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Koninklijke Philips NV stock overvalued right now?
Based on GuruFocus' analysis, Koninklijke Philips NV (RYLPF) is currently considered Fairly Valued. The stock's GF Value™ is $26.00, compared to a current price of $28.01 — trading 7.7% above its estimated fair value. The current Debt-to-EBITDA is 3.76, which is 40% above median its 10-year median of 2.69 and 141.8% above the Medical Devices & Instruments industry median of 1.56. Koninklijke Philips NV's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Koninklijke Philips NV (RYLPF), the current Debt-to-EBITDA is 3.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Koninklijke Philips NV (RYLPF) Overvalued in 2026?
Based on GuruFocus' analysis, Koninklijke Philips NV stock appears to be overvalued.
The current stock price of $28.01 is trading 7.7% above its estimated GF Value™ of $26.00.
GuruFocus considers Koninklijke Philips NV to be Fairly Valued.
Key valuation signals for RYLPF:
Debt-to-EBITDA: 3.76 (40% above median its 10-year median of 2.69)
GF Value™: $26.00 vs. price of $28.01 (7.7% above fair value)
Industry Position: 141.8% above the Medical Devices & Instruments median (#329 of 468)
No single metric tells the full story. See the RYLPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound and X-ray equipment, and image-guided therapy solutions. The connected care segment (under 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal-care products.
70GF Score
Get the complete analysis for RYLPF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RYLPF has been successfully added to your 
